{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:35:19Z","timestamp":1786977319463,"version":"build-2736575974"},"reference-count":21,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2020,3,13]],"date-time":"2020-03-13T00:00:00Z","timestamp":1584057600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2020,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To investigate whether palonosetron is better than granisetron in preventing chemotherapy\u2010induced nausea and vomiting (CINV) in a three\u2010drug combination with dexamethasone and fosaprepitant (Fos) in patients with breast cancer who are placed on anthracycline and cyclophosphamide (AC\u2010based regimen).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>Chemo\u2010naive women with primary breast cancer were randomly administered either palonosetron 0.75\u00a0mg (day 1) or granisetron 1\u00a0mg (day 1) combined with dexamethasone (12\u00a0mg at day 1, 8\u00a0mg at day 2 and day 3) and Fos 150\u00a0mg (day 1) before receiving AC\u2010based regimen in a double\u2010blind study. The primary endpoint was the complete response (CR) rate of emesis in cycle 1 in the delayed phase. This was defined as neither vomiting nor rescue drug usage for emesis at &gt;24\u2010120\u00a0hours after chemotherapy. Secondary endpoints were the CR in the acute\/overall phase (0\u201024\/0\u2010120\u00a0hours, respectively, after chemotherapy), no nausea and vomiting, Patient\u2010Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO\u2010CTCAE), and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      From December 2012 to October 2014, 326 patients were treated and evaluated (164\/162 evaluable patients in granisetron\/palonosetron arm, respectively). The CR during the delayed phase was 60.4% in the granisetron regimen and 62.3% in the palonosetron regimen. The CR during acute phase (73.2% vs 75.9%, respectively) and the CR during overall phase (54.9% in both regimens) were very identical. A significantly higher number of patients in the palonosetron arm were free from nausea during the delayed phase (28% vs 40.1%;\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a0.029). Adverse events were also identical, although infusion site reactions (ISR) were higher (20.3%\u201023.3%) than preceding studies in both regimens.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In combination with dexamethasone and Fos, this study suggests that palonosetron is not better than granisetron in chemo\u2010naive patients with primary breast cancer receiving AC\u2010based regimen. Administration of Fos in peripheral veins after AC\u2010based regimen increased ISR.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cam4.2979","type":"journal-article","created":{"date-parts":[[2020,3,13]],"date-time":"2020-03-13T18:29:03Z","timestamp":1584124143000},"page":"3319-3327","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["A double\u2010blind, randomized, multicenter phase 3 study of palonosetron vs granisetron combined with dexamethasone and fosaprepitant to prevent chemotherapy\u2010induced nausea and vomiting in patients with breast cancer receiving anthracycline and cyclophosphamide"],"prefix":"10.1002","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1907-0247","authenticated-orcid":false,"given":"Koji","family":"Matsumoto","sequence":"first","affiliation":[{"name":"Hyogo Cancer Center Hyogo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Takahashi","sequence":"additional","affiliation":[{"name":"NHO Hokkaido Cancer Center Hokkaido Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Sato","sequence":"additional","affiliation":[{"name":"Tokyo\u2010West Tokushukai Hospital Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Osaki","sequence":"additional","affiliation":[{"name":"Saitama Medical University Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshimi","family":"Takano","sequence":"additional","affiliation":[{"name":"Toranomon Hospital Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8490-9064","authenticated-orcid":false,"given":"Yoichi","family":"Naito","sequence":"additional","affiliation":[{"name":"National Cancer Center Hospital East Kashiwa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Matsuura","sequence":"additional","affiliation":[{"name":"Hiroshima Prefectural Hospital Hiroshima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenjiro","family":"Aogi","sequence":"additional","affiliation":[{"name":"Shikoku Cancer Center Ehime Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimiko","family":"Fujiwara","sequence":"additional","affiliation":[{"name":"Kindai University Hospital Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Tamura","sequence":"additional","affiliation":[{"name":"National Cancer Center Hospital Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoi","family":"Baba","sequence":"additional","affiliation":[{"name":"Hokkaido University Hokkaido Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Tokunaga","sequence":"additional","affiliation":[{"name":"Osaka City General Hospital Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gen","family":"Hirano","sequence":"additional","affiliation":[{"name":"Kyushu Hospital Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Imoto","sequence":"additional","affiliation":[{"name":"Kyorin University Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chieko","family":"Miyazaki","sequence":"additional","affiliation":[{"name":"Jichi Medical University Tochigi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Yanagihara","sequence":"additional","affiliation":[{"name":"Kansai Electric Power Hospital Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiyo K.","family":"Imamura","sequence":"additional","affiliation":[{"name":"Advanced Cancer Translational Research Institute Showa University Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasutaka","family":"Chiba","sequence":"additional","affiliation":[{"name":"Kindai University Hospital Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4700-4781","authenticated-orcid":false,"given":"Toshiaki","family":"Saeki","sequence":"additional","affiliation":[{"name":"Saitama Medical University Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,3,13]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.3635"},{"key":"e_1_2_10_3_1","unstructured":"Network NCC. NCCN Cliincal Practice Guidlines in Oncology Antiemesis.2012."},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw270"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70313-9"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2010-0198"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.34.4614"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.7859"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp195"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp243"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg417"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl137"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11817"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.09.050"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2010.01689.x"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw220"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-010-0944-4"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-015-0786-7"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1515725"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.4789"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-013-2089-8"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.4375"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcam4.2979","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.2979","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.2979","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.2979","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T21:06:18Z","timestamp":1693947978000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.2979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,13]]},"references-count":21,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["10.1002\/cam4.2979"],"URL":"https:\/\/doi.org\/10.1002\/cam4.2979","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,13]]},"assertion":[{"value":"2019-07-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}